Phosplatin Therapeutics is a clinical-stage pharmaceutical company focused on oncology therapeutics and holds the exclusive global license to phosphaplatins, a family of small molecules designed to overcome drug resistance and toxicity. Its lead candidate, PT-112, is a novel chemical entity in clinical development that exhibits immunogenic cell death and osteotropism. The company is advancing PT-112 both as a monotherapy and in combination with PD-L1 immune checkpoint inhibition. It is sponsoring an ongoing clinical study of PT-112 with the PD-L1 inhibitor avelumab under a collaboration with Pfizer and Merck KGaA (EMD Serono in the US and Canada). Management intends to use newly raised capital to complete Phase 2 development of PT-112 and to support planning for intended pivotal trials. To date, the company has raised $56m in equity capital since inception.

Total raised

$18M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2020